Eternal Search · Ratings · Project Ratings
Bioreplacement
Regenerative medicine, tissue engineering, and organ replacement.
#OverallProjectSci / Brk / Inv
152.9Frontier Bio
Frontier Bio is a U.S. tissue-engineering startup pursuing two linked product lines: a patient-seeded, bioresorbable vascular graft intended for implantation and remodeling into a living blood vessel, and human tissue models such as lung and blood-brain-barrier/neural systems for preclinical testing. The central promise is plausible in concept and supported by repeated, fairly consistent company and interview claims, some partnership signals, and early preclinical/research-use positioning, but the evidence here is still weak on independent validation: most sources are company-controlled, interview-based, press-style, or investor-marketing materials, and the excerpts do not provide robust methods, sample sizes, peer-reviewed outcomes, or clinical data.Sci 46.3Brk 62.0Inv 52.9
53%
→
249.0Kind Bio
Kind Bio is a U.S. startup pursuing an "integrated organ network" platform: genetically engineered animal systems designed to grow transplantable peripheral organs while lacking higher CNS function and a normal body plan. The core promise is abundant organ supply for transplantation and, longer term, multi-organ replacement for age-related decline. The evidence is still early and mostly self-described or patent-based; there is no peer-reviewed demonstration here of functional human-ready organs, clinical efficacy, or scalable manufacturing.Sci 37.8Brk 77.6Inv 40.9
49%
→
340.7Wearable regenerative bioreactor for controlled wound healing
BioDome-R is an early-stage academic proof-of-concept for a small wearable regenerative bioreactor that creates a sealed local wound microenvironment and delivers short-term pro-regenerative cues in small-animal models. The strongest support in the provided evidence is not clinical efficacy but plausibility: related literature supports the relevance of mechanochemical control, wearable hydrogel patches, and flexible wound bioelectronics, while the project-specific evidence shows a concrete preclinical plan, explicit safety endpoints, and a narrow immediate goal of testing feasibility, tolerability, and biological response rather than claiming regeneration or translation.Sci 49.9Brk 40.0Inv 33.1
41%
→